If your biotech or life sciences organization stores electronic records or applies electronic signatures to regulated data, 21 CFR Part 11 compliance isn’t optional—it’s the difference between a smooth FDA audit and a costly Form 483 observation. Yet for many growing labs in Boston, Cambridge, and the greater New England biotech corridor, Part 11 remains one of the most misunderstood corners of IT and quality management.
This guide breaks down exactly what 21 CFR Part 11 requires, the IT controls that make or break compliance, and a practical checklist you can use to assess where your systems stand today.
What Is 21 CFR Part 11?
21 CFR Part 11 is the FDA regulation that defines the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records and handwritten signatures. In plain terms: if the FDA can inspect it and you want your digital data to count, it has to meet Part 11.
The regulation applies to any FDA-regulated industry that creates, modifies, maintains, archives, retrieves, or transmits records in electronic form—pharmaceutical manufacturers, biotech firms, medical device companies, clinical research organizations, and the labs that support them.
The Core Requirements of Part 11
Part 11 compliance rests on a handful of pillars. Each one has direct IT implications:
1. Audit Trails
Systems must automatically record the who, what, and when of every create, modify, or delete action on a regulated record—without allowing users to alter or disable the log. A compliant audit trail is time-stamped, attributable to a specific individual, and permanently retained.
2. Access Controls and Authentication
Only authorized individuals can access regulated systems. This means unique user accounts (never shared logins), role-based permissions, automatic session timeouts, and—increasingly expected by auditors—multi-factor authentication. Password policies must enforce complexity and periodic rotation.
3. Electronic Signatures
Electronic signatures must be uniquely linked to one individual, include the signer’s printed name, the date and time, and the meaning of the signature (review, approval, authorship). They cannot be copied, transferred, or reused by anyone else.
4. System Validation
Any system handling Part 11 records must be validated to demonstrate it performs consistently and as intended. Validation documentation—installation qualification, operational qualification, and performance qualification—is one of the first things an FDA inspector asks to see.
5. Data Integrity and Backups
Records must remain accurate and retrievable throughout their retention period. That requires secure, tested backups, disaster recovery planning, and protection against unauthorized modification—the ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available) are the standard auditors measure against.
Your Part 11 IT Compliance Checklist
- Every regulated system enforces unique, individual user accounts with role-based access
- Multi-factor authentication is enabled on all systems touching regulated data
- Automatic, tamper-proof audit trails are active and regularly reviewed
- Electronic signature workflows capture name, timestamp, and signing intent
- All GxP systems have current validation documentation (IQ/OQ/PQ)
- Backups are automated, encrypted, off-site, and—critically—restore-tested
- A documented disaster recovery plan exists and has been exercised in the last 12 months
- Access is promptly revoked when employees leave or change roles
- Vendor systems (ELN, LIMS, QMS) have Part 11 compliance documentation on file
Where Most Biotech Labs Fall Short
In our experience supporting regulated organizations across Boston and Nashua, the most common Part 11 gaps aren’t in the lab software itself—they’re in the surrounding IT infrastructure. Shared admin accounts, backups that were never restore-tested, missing MFA, and audit trails nobody actually reviews are the findings that turn up again and again. The software vendor gives you a Part 11-capable tool; whether your environment is compliant is on you.
Turning Compliance Into a Competitive Advantage
For an emerging biotech, being able to walk an investor, partner, or FDA auditor through a clean, validated, Part 11-compliant IT environment is a signal of operational maturity. It shortens due diligence, de-risks partnerships, and prevents the scramble that happens when an audit lands unexpectedly.
Frequently Asked Questions
Does Part 11 apply to cloud and SaaS systems?
Yes. Cloud-hosted ELN, LIMS, and document management systems must meet the same Part 11 requirements. You’re responsible for confirming the vendor provides audit trails, access controls, and validation support—and for configuring them correctly.
How often should audit trails be reviewed?
Audit trail review should be risk-based and periodic—many organizations review on a defined schedule and always before batch release or data submission. The key is that review actually happens and is documented.
Part 11 vs. Data Integrity: Why They Go Hand in Hand
It’s common to hear “Part 11” and “data integrity” used interchangeably, but they’re related rather than identical. Part 11 is the U.S. regulation governing electronic records and signatures. Data integrity is the broader principle—captured in the ALCOA+ framework—that your data is complete, consistent, and trustworthy across its entire lifecycle. Part 11 is essentially the technical enforcement mechanism that makes data integrity provable in an electronic environment.
The practical takeaway for a lab: passing a Part 11 checklist on paper isn’t enough if your day-to-day practices undermine data integrity. An audit trail that exists but is never reviewed, or a backup that runs nightly but has never been successfully restored, will still generate findings. Auditors increasingly look past documentation to test whether controls actually function.
Common ELN and LIMS Compliance Pitfalls
Electronic lab notebooks (ELNs) and laboratory information management systems (LIMS) sit at the heart of most biotech data workflows, which makes them a frequent audit focus. The pitfalls we see most often include default configurations that leave audit trails disabled, generic service accounts used for integrations, unclear ownership of validation between the vendor and the lab, and orphaned accounts belonging to departed employees that were never deactivated.
None of these are exotic problems. They’re the natural result of a fast-moving startup prioritizing science over IT governance—which is exactly why a compliance-focused managed IT partner pays for itself. The goal is to build controls into your infrastructure once, correctly, so compliance becomes the default rather than a fire drill before every audit.
How Cloud Cat Approaches Part 11 Readiness
Our process starts with a gap assessment of your current environment against Part 11 and ALCOA+, mapped to the specific systems you use. From there we prioritize remediation by risk—closing the gaps most likely to generate a finding first—then implement the access controls, MFA, tamper-proof logging, and restore-tested backup and disaster recovery that stand up to inspection. Finally, we document everything, because in a regulated environment, undocumented compliance is the same as no compliance.
Get a Part 11 Readiness Assessment
Not sure whether your IT environment would survive an FDA inspection? Cloud Cat Services specializes in secure, compliant managed IT for biotech and life sciences teams across Boston, Cambridge, and Nashua. We’ll review your systems against Part 11 requirements and give you a clear, prioritized roadmap.
Book your free IT & compliance assessment today →
